Ovascience, Inc.

Other

Dana-farber-cancer Institute Inc.

Hefei Tairui Biotechnology Co., Ltd.

Daiamed, Inc.

David T Weaver

Michael Rynkiewicz

Bo Zhang

Jian Lin

Lei Jin

Thomas D Bannister

Alan D D'Andrea

Sherin Salaheldin Abdel-Meguid

Markus Grompe

Hongfeng Deng

Harold V Meyers

Robert Edward Babine

Cheng Cao

Yanwen Jin

Richard Kennedy

Zihong Gho

Scott R Magee

Pramod Pandey

This present invention compositions and methods of treating cancer and methods of accessing/monitoring the responsiveness of a cancer cell to a therapeutic compound.

Treating cancer deficient in FANCA, FANCD2, FANCE, or FANCG with an ATM inhibitor

Anti-VASA antibodies (mAbs), particularly humanized mAbs that specifically bind to VASA with high affinity, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-VASA mAbs are provided. The disclosure also provides nucleic acid molecules encoding the anti-VASA mAbs, expression vectors, host cells, methods for making the anti-VASA mAbs, and methods for expressing the anti-VASA mAbs. Finally, methods of using the anti-VASA mAbs to isolate and/or purify cells expressing VASA are disclosed.

Anti-vasa antibodies, and methods of production and use thereof

Anti-VASA antibodies, and methods of production and use thereof

A humanized anti-EGFR antibody L4-H3 and gene encoding the antibody are disclosed. The antibody is composed of a heavy chain and a light chain. The amino acid sequence of the heavy chain variable region is shown as positions 1-145 of SEQ ID NO: 3, the heavy chain constant region is the heavy chain constant region of the human antibody IgG1, and the amino acid sequence of the light chain is shown as SEQ ID NO: 1.

Humanized anti-EGFR antibody L4-H3 and coding gene thereof

Disclosed herein is the use of three-dimensional structure information to guide the process of modifying antibodies with amino acids from one or more templates or surrogates such that the antigen binding properties of the parent antibody are maintained and the immunogenicity potential is reduced when administered as a therapeutic in humans.

Methods for humanizing antibodies and humanized antibodies made thereby

The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention also provides three-dimensional structures of Factor XIa and methods for designing or selecting additional Factor XIa inhibitors using these structures.

Compounds and methods for treatment of thrombosis

Growing community of inventors

Newton, MA, United States of America

David T Weaver